Related Experiment Video
Updated: May 28, 2026
09:47
DeepOmicsAE: Representing Signaling Modules in Alzheimer's Disease with Deep Learning Analysis of Proteomics, Metabolomics, and Clinical Data
Published on: December 15, 2023
Classification of Alzheimer's disease using a self-smoothing operator
Juan Eugenio Iglesias1, Jiayan Jiang, Cheng-Yi Liu
1Laboratory of Neuro Imaging, University of California, Los Angeles, USA. jeiglesias@ucla.edu
Medical Image Computing and Computer-Assisted Intervention : MICCAI ... International Conference on Medical Image Computing and Computer-Assisted Intervention
|October 19, 2011
Summary
This study introduces a new system for Alzheimer's disease classification using enhanced similarity measures and a diffusion process. The system achieves state-of-the-art accuracy in identifying normal, mild cognitive impairment, and Alzheimer's disease from brain MRIs.
Area of Science:
- Medical Imaging Analysis
- Machine Learning for Healthcare
- Neurodegenerative Disease Research
Background:
- Alzheimer's disease (AD) diagnosis relies on accurate classification of neuroimaging data.
- Existing methods for AD classification using MRI data have limitations in capturing complex relationships.
Purpose of the Study:
- To develop and evaluate a novel system for Alzheimer's disease classification using enhanced similarity measures.
- To improve the accuracy of classifying normal, mild cognitive impairment (MCI), and Alzheimer's disease (AD) using brain MRI data.
Main Methods:
- A system was developed to learn and fuse registration-based and overlap-based similarity measures.
- A self-smoothing operator (SSO) was employed to enhance these similarity measures.
- A diffusion process was used on a pair-wise affinity matrix to propagate affinity mass along the intrinsic data space, creating an enhanced metric.
- Nearest neighborhood classification was performed using the enhanced metric.
Main Results:
- The proposed system demonstrated significantly improved accuracy for Alzheimer's Disease classification compared to Diffusion Maps and a popular metric learning approach.
- State-of-the-art classification results were achieved on 120 brain MRIs from the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset.
- Accurate differentiation was achieved between normal cognition, mild cognitive impairment, and Alzheimer's disease.
Conclusions:
- The developed system effectively classifies Alzheimer's disease using enhanced similarity measures and a diffusion process.
- This approach offers a promising advancement for accurate and early diagnosis of Alzheimer's disease from MRI data.
- The method shows superior performance over existing techniques, highlighting its potential clinical utility.
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...